Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.
We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
We have pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. We discovered, are developing and control 100% worldwide rights to our proprietary uroguanylin based GI platform that includes one commercial product, TRULANCE® (plecanatide), and a second lead product candidate, dolcanatide.
We are based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Synergy [SGYP] became a public company in July 2008 and is currently listed on NASDAQ.
No information provided